PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in ...

GSK has reported new clinical data pointing to a benefit with its respiratory syncytial virus (RSV) vaccine Arexvy when used to treat a younger age group than the over-60s for whom it is approved.

RSV-A nAbs: SCB-1019 induced GMTs in RSV-A nAbs of approximately 30,500 IU/mL, compared to approximately 26,700 IU/mL for AREXVY and approximately 3,300 IU/mL for placebo at Day 28. RSV-B nAbs ...

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by respiratory syncytial virus due to certain ...

The drugmaker said sales of Arexvy fell sharply in the third quarter, but cancer and HIV treatments saw a stronger performance. Drugmaker GSK saw a sharp drop in revenue from its blockbuster ...

RSV-A nAbs: SCB-1019 induced GMTs in RSV-A nAbs of approximately 30,500 IU/mL, compared to approximately 26,700 IU/mL for AREXVY and approximately 3,300 IU/mL for placebo at Day 28. RSV-B nAbs: ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory ...

GSK (GSK) announced that Japan’s Ministry of Health, Labour and Welfare, MHLW, has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV disease to ...

(RTTNews) - GSK plc (GSK, GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV ...